Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(UCLA Health), Beverly Moy(Global Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Seth A. Wander(Harvard University), Neelima Vidula(Harvard University), Phoebe Ryan(Harvard University), Leif W. Ellisen(Harvard University), Geoffrey Fell(Harvard University), Elizabeth Abraham(Temple College), Steven J. Isakoff(Harvard University), Jennifer Shin(Massachusetts General Hospital), Arielle J. Medford(Harvard University)
Cited by 53
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k